- Home
- WTTR vs SION Comparison
WTTR vs SION Comparison
Compare WTTR & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTTR
- SION
- Stock Information
- Founded
- WTTR 2016
- SION 2019
- Country
- WTTR United States
- SION United States
- Employees
- WTTR N/A
- SION N/A
- Industry
- WTTR Oilfield Services/Equipment
- SION
- Sector
- WTTR Energy
- SION
- Exchange
- WTTR Nasdaq
- SION NYSE
- Market Cap
- WTTR 922.1M
- SION 871.7M
- IPO Year
- WTTR 2017
- SION 2025
- Fundamental
- Price
- WTTR $9.73
- SION $19.10
- Analyst Decision
- WTTR Strong Buy
- SION Strong Buy
- Analyst Count
- WTTR 4
- SION 1
- Target Price
- WTTR $14.88
- SION $32.00
- AVG Volume (30 Days)
- WTTR 1.2M
- SION 274.0K
- Earning Date
- WTTR 08-05-2025
- SION 08-25-2025
- Dividend Yield
- WTTR 2.88%
- SION N/A
- EPS Growth
- WTTR N/A
- SION N/A
- EPS
- WTTR 0.34
- SION N/A
- Revenue
- WTTR $1,459,911,000.00
- SION N/A
- Revenue This Year
- WTTR $2.68
- SION N/A
- Revenue Next Year
- WTTR $5.03
- SION N/A
- P/E Ratio
- WTTR $28.21
- SION N/A
- Revenue Growth
- WTTR N/A
- SION N/A
- 52 Week Low
- WTTR $7.20
- SION $7.26
- 52 Week High
- WTTR $15.14
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- WTTR 60.41
- SION N/A
- Support Level
- WTTR $9.34
- SION N/A
- Resistance Level
- WTTR $9.97
- SION N/A
- Average True Range (ATR)
- WTTR 0.37
- SION 0.00
- MACD
- WTTR 0.02
- SION 0.00
- Stochastic Oscillator
- WTTR 74.54
- SION 0.00
About WTTR Select Water Solutions Inc.
Select Water Solutions Inc provides sustainable water and chemical solutions to the energy industry. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. Its reportable segments are Water Services, Water Infrastructure and Chemical Technologies. It generates the majority of its revenue from Water Services segment.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.